246231-75-4

Basic information

• Product Name: 4(1H)-Quinazolinone, 7-methoxy-2-phenyl-
• CAS NO: 246231-75-4
• Molecular Formula: C15H12N2O2
• Molecular Weight: 252.272
• Mol File: 246231-75-4.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 4(1H)-Quinazolinone, 7-methoxy-2-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Quinazolinone, 7-methoxy-2-phenyl-(246231-75-4)
• EPA Substance Registry System: 4(1H)-Quinazolinone, 7-methoxy-2-phenyl-(246231-75-4)

Safety Data

• Hazardous Substances Data: 246231-75-4(Hazardous Substances Data)

Upstream product

• 698-16-8 benzohydroximoyl chloride 
• 932-90-1 Benzaldoxime 
• 1452311-14-6 (Z)-N'-hydroxy-N-(4-methoxybenzyl)benzimidamide 
• 74317-85-4 2-bromo-4-methoxybenzoic acid 
• 1670-14-0 benzamidine monohydrochloride 
• 38487-91-1 2-amino-p-anisamide 
• 100-51-6 benzyl alcohol 
• 201230-82-2 carbon monoxide 
• 51031-91-5 N-(3-methoxyphenyl)benzimidamide 
• 1224442-31-2 N-[imino(phenyl)methyl]-4-methoxy-2-nitrobenzamide 
• 51031-91-5 (Z)-N'-(3-methoxyphenyl)benzimidamide 
• 98-88-4 benzoyl chloride 
• 36364-17-7 5-(4-methoxyphenyl)-3-phenyl-1,2,4-oxadiazole 
• 103-71-9 phenyl isocyanate 

Downstream Products

• 923274-29-7 (1R,2R,4R)-2-((1R,2S)-1-ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-(7-methoxy-2-phenyl-quinazolin-4-yloxy)-cyclopentanecarboxylic acid tert-butyl ester 
• 923274-31-1 (1R,2S)-ethyl 1-((1R,2R,4R)-2-(hex-5-enyl(methyl)carbamoyl)-4-(7-methoxy-2-phenylquinazolin-4-yloxy)cyclopentanecarboxamido)-2-vinylcyclopropanecarboxylate 
• 923274-30-0 (1R,2R,4R)-2-((1R,2S)-1-ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-(7-methoxy-2-phenyl-quinazolin-4-yloxy)-cyclopentanecarboxylic acid 
• 371946-85-9 4-oxo-2-phenyl-3,4-dihydroquinazolin-7-yl acetate 

Relevant articles and documents

Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors

Aurora kinases play critical roles in the regulation of the cell cycle and mitotic spindle assembly. Aurora A kinase, a member of the Aurora protein family, is frequently highly expressed in tumors, and selective Aurora A inhibition serves as a significant component of anticancer therapy. However, designing highly selective Aurora A inhibitors is difficult because Aurora A and B share high homology and differ only by three residues in their ATP-binding pockets. Through structure-based drug design, we designed and synthesized a series of novel quinazolin-4-amine derivatives. These derivatives act as selective Aurora A kinase inhibitors by exploiting the structural differences between Aurora A and B. The selectivities of most compounds were improved (the best up to >757-fold) when comparing with the lead compound (3-fold). In vitro biochemical and cellular assays revealed that compound 6 potently inhibited Aurora A kinase and most human tumor cells. Furthermore, compound 6 effectively suppressed carcinoma, such as triple-negative breast cancers (TNBC) in an animal model. Therefore, compound 6 might serve as a promising anticancer drug. Moreover, through molecular dynamic (MD) analysis, we have identified that a salt bridge formed in Aurora B is key contributor for the isoform selectivity of the inhibitor. This salt bridge has not been previously detected in the reported crystal structure of Aurora B. These results might provide a crucial basis for the further development of highly potent inhibitors with high selectivity for Aurora A.

Oxidant- and metal-free synthesis of 4(3H)-quinazolinones from 2-amino-N-methoxybenzamides and aldehydes via acid-promoted cyclocondensation and elimination

A series of biologically important 4(3H)-quinazolinones were readily synthesized in good to excellent yields from 2-amino-N-methoxybenzamides and aldehydes via a cascade reaction consisting of AcOH-promoted cyclocondensation and elimination. The current m

Fe3O4 nanoparticle-supported copper(I): Magnetically recoverable and reusable catalyst for the synthesis of quinazolinones and bicyclic pyrimidinones

A highly efficient, easily recoverable and reusable Fe3O 4 magnetic nanoparticle-supported Cu(I) catalyst has been developed for the synthesis of quinazolinones and bicyclic pyrimidinones. In the presence of supported Cu(I) catalyst (10 mol%), amidines reacted with substituted 2-halobenzoic acids and 2-bromocycloalk-1-enecarboxylic acids to generate the corresponding N-heterocycle products in good to excellent yields at room temperature in DMF. In addition, the supported Cu(I) catalyst could be recovered at least 10 times without significant loss of its catalytic activity. Copyright